Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
RESEARCH ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 2026 AACR ANNUAL MEETING

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that two preclinical pipeline research results will be presented at the 2026 American Association for Cancer Research ("**AACR**") Annual Meeting, to be held at the San Diego Convention Center, San Diego, California, United States, from April 17 to 22, 2026. The two presentations showcase the Company's innovative research in T cell engager-drug conjugates (TDC) and bispecific-targeted ADCs, further validating the synergistic research and development strategy of the Company's three core proprietary technology platforms: LeadsBody™ (CD3 T-Cell Engager platform), X-body™ (4-1BB Engager platform), and TOPiKinetics™ (ADC technology platform).

Details of the presentations are as follows:

LBL-054 TDC Poster Presentation

LBL-054 TDC is a first-in-class globally CDH17-targeted bispecific ADC developed on the Company's proprietary antibody platform, incorporating the Company's proprietary TOPiKinetics™ linker-payload. By combining the dual mechanisms of TCE and ADC, it is designed to achieve highly effective and low-toxicity precision treatment for gastrointestinal tumors including colorectal cancer, gastric cancer, and pancreatic cancer.

Preclinical studies demonstrate that LBL-054 TDC can combine the potent direct killing effect of an ADC with the T cell redirection and activation of a TCE both in vitro and in vivo, exhibiting strong binding and internalization in tumor cells with potent cytotoxicity, while showing weak binding, no internalization, and no cytotoxicity in T cells. In T cell-dependent cellular cytotoxicity (TDCC) assays, LBL-054 TDC induced potent cytotoxicity across varying effector-to-target ratios and CDH17 expression levels, with lower cytokine release compared to conventional TCEs. LBL-054 TDC also mediates potent bystander killing of CDH17-negative tumor cells without affecting T cells. In the MC38/hCDH17 syngeneic mouse model, LBL-054 TDC demonstrated superior anti-tumor efficacy compared to both TCE and ADC. In a 4-week dose-range finding (DRF) study in cynomolgus monkeys, LBL-054 TDC was well tolerated following repeated intravenous infusion.

- **Abstract Title:** LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer
- **Presentation Format:** Poster
- **Location:** Section 17, Poster Board#26
- **Date & Time:** April 21, 2026 (Tuesday) | 14:00 – 17:00 PT
- **Abstract Number:** 5857

LBL-061 Poster Presentation

LBL-061 is a novel EGFR/PD-L1 bispecific ADC conjugated via the Company's proprietary TOPiKinetics™ linker-payload platform. It combines the tumor-targeted killing of an ADC with immune activation, synergistically enhancing anti-tumor effects, and is suitable for solid tumors including head and neck cancer, non-small cell lung cancer, and nasopharyngeal carcinoma.

Preclinical studies show that LBL-061 exhibits potent binding and cytotoxicity against a range of tumor cell lines, along with strong PD-1/PD-L1 blocking activity. In a PBMC-tumor cell co-culture system, it can induce immunogenic cell death (ICD) in tumor cells and mediate a potent bystander effect on EGFR-negative tumor cells. In vivo studies demonstrate excellent tumor growth inhibition in both syngeneic and xenograft mouse models. In a 6-week dose-range finding (DRF) study in cynomolgus monkeys, LBL-061 was well tolerated following repeated intravenous infusion (Q3W dosing regimen), with the highest non-severely toxic dose (HNSTD) reaching 40 mg/kg.

- **Abstract Title:** LBL-061: A novel EGFRxPD-L1 targeted drug conjugate for the treatment of multiple solid tumors
- **Presentation Format:** Poster
- **Location:** Section 8, Poster Board#20
- **Date & Time:** April 21, 2026 (Tuesday) | 14:00 – 17:00 PT
- **Abstract Number:** 5601

Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, March 31, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng and Dr. Chen Renhai as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.